Phase I Trial Improves Mesothelioma Survival More Than 200%

Sellas Life Sciences reports its Phase I clinical trial showed improvement of overall survival in patients with pleural mesothelioma. The study focused on a new potential therapy called GPS (galinpepimut-S), an immunotherapy vaccine. The trial included 10 patients with relapsed or refractory mesothelioma, nine of whom received at least three doses of GPS. Researchers gave the third dose of GPS alongside the checkpoint inhibitor Opdivo (nivolumab).  President of Sellas, Angelos Stergiou, stated in a press release, “As we had hypothesized in the past, this increase in survival appears to be consistent with long-term immunity-mediated antitumor effect with our immunotherapy combination as we had seen in other studies with GPS.” “Importantly, the positive survival outcomes seen in this study are accompanied by a safety profile similar to that of the checkpoint inhibitor alone,” said Stergiou. “We believe that these observed survival benefits … contribute to stopping the progression of extremely aggressive cancers and demonstrate its utility as a potentially effective combination therapy.“ GPS and Opdivo Combination More Than Triples Survival All patients enrolled in the trial achieved a median progression-free survival of 11.9 weeks or about three months without any increase in cancer growth. A third of patients had stable disease with a tumor decrease of 17%.  The median age of patients in the study was 69 years, and 60% enrolled with a ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Clinical Trials/Research/Emerging Treatments Immunotherapy Mesothelioma Source Type: news